Serum Apelin 13 Levels in Patients With Pulmonary Embolism

Basit Öğe Kaydı
dc.contributor.authorSen, Hadice Selimoglu
dc.contributor.authorKaplan, Ibrahim
dc.contributor.authorAbakay, Ozlem
dc.contributor.authorSezgi, Cengizhan
dc.contributor.authorYilmaz, Sureyya
dc.contributor.authorTaylan, Mahsuk
dc.contributor.authorAbakay, Abdurrahman
dc.date.accessioned2024-04-24T17:14:40Z
dc.date.available2024-04-24T17:14:40Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction and Aim: Expression and peptide immunoreactivity of apelin messenger RNA have been described in a variety of tissues, including gastrointestinal tract, adipose tissue, brain, kidney, liver, cardiovascular system, and lungs. This study aimed to investigate the possible involvement of the endogenous apelin in the pathophysiological events that occur in patients with pulmonary embolism (PE). Materials and Methods: In total, 53 patients with PE and 35 healthy volunteers were included the study. This cross-sectional study was conducted at a tertiary care university hospital and among patients diagnosed as having PE. The control group consisted of healthy volunteers who applied to hospital for a routine checkup examination. Serum apelin 13 levels were measured in both the groups and their results were compared. Results: The median ages were 57 and 53 years, and female-male ratios were 30/23 and 20/15, in the PE and control groups, respectively. The mean serum apelin 13 levels were found to be significantly higher in the PE group (76.94 10.70 ng/mL) than in the control group (50.01 +/- 7.13 ng/mL; P < .001). Conclusion: This study demonstrated that apelin 13 levels are elevated in patients with PE. These results suggest that apelin may be a novel biomarker and a potential therapeutic target in patients with acute PE in the future.en_US
dc.identifier.doi10.1177/1076029615572467
dc.identifier.endpage547en_US
dc.identifier.issn1076-0296
dc.identifier.issn1938-2723
dc.identifier.issue6en_US
dc.identifier.pmid25693918
dc.identifier.scopus2-s2.0-84982897393
dc.identifier.scopusqualityQ2
dc.identifier.startpage543en_US
dc.identifier.urihttps://doi.org/10.1177/1076029615572467
dc.identifier.urihttps://hdl.handle.net/11468/18127
dc.identifier.volume22en_US
dc.identifier.wosWOS:000382449800006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofClinical and Applied Thrombosis-Hemostasis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectApelin 13en_US
dc.subjectPulmonary Embolismen_US
dc.subjectAdipokinesen_US
dc.titleSerum Apelin 13 Levels in Patients With Pulmonary Embolismen_US
dc.titleSerum Apelin 13 Levels in Patients With Pulmonary Embolism
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu